Adaptimmune Therapeutics PLC — Director's Dealing 2021

Mar 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2021-03-03

Reporting Person: TAYTON-MARTIN HELEN KATRINA (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-03	Ordinary Shares with a nominal value of GBP0.001 per share	M	1785000	$0.157	Acquired	1800000	Direct

Footnotes

F1: The ordinary shares whose purchase is reported on this line were obtained from the exercise of share options that were granted on March 20, 2015. The ordinary shares continue to be held by the Reporting Person.

F2: The price reported in Column 4 of $0.157 per ordinary share is derived from the option purchase price paid on March 3, 2021 of GBP0.112 per ordinary share.

F3: The 1,800,000 ordinary shares reported in Column 5 include 1,785,000 ordinary shares reported in Column 4 as well as 15,000 ordinary shares held by the Reporting Person. The ordinary shares reported in Column 5 represent solely the ordinary shares beneficially owned by the Reporting Person. Additionally, the Reporting Person holds options covering an aggregate of 9,703,672 ordinary shares of the Issuer. Ordinary shares may be represented by American Depositary Shares (ADSs) with each ADS representing six ordinary shares.